N E W S  &  U P D A T E S

I N T E G R A T I V E   C A N C E R   T R E A T M E N T S

Guardant Health and Collaborators Present Further Clinical Utility Data for Guardant360 at the AACR-NCI-EORTC International Conference On Molecular Targets and Cancer Therapeutics


AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care
May 12 - 15th, 2016, Orlando, FL.
Abstract entitled Invitro and invivo proof of concept for an effective antineoplastic combination 
of novel anti HIF therapy in pancreatic cancer

Dr. Nezami Chairing molecular profiling at International Conference on cancer (ICOR), Oct 2016, Dubai, UAE 
Abstract entitled " Correlatin of amplification/expression of C-MYC gene and survival time amongst patients with cancer"

"Chemoprevention and Epigenetic Multitargeted Approach"
Dana-Farber Cancer Institute, Cancer Survivorship Symposium: Advancing Care and Research
Journal of Clinical Oncology 34, 2016 ( Suppl 3S, Abstr e297)

Dr.Nezami presentation PDF
"Prognostic Surrogate markers for survival, a case series for a novel antiangiogenic therapy 
(Multitargeted Epigenetic Therapies/MTET)

Journal of Biology and Medicine
"The role of Telomeres in Cancer development and progression, 
and the Double Edged Sword effect with Tamoxifen" 
M. Nezami, S. Hager and J. Garner
778.9 KB

 Dr.Nezami presentation at the Society of Integrative Oncology (SIO) 
(click the link below for more information)

EMT and Anti-EMT Strategies in Cancer
[Download]  Download as PDF (Size:316KB)  HTML   XML  PP. 1013-1019  
DOI: 10.4236/jct.2015.611110  

(Vol.6 No.11 2015) of Journal of Cancer Therapy (JCT)
(Vol.7 No.1 January 2016) of Journal of Cancer Therapy (JCT)
"Correlation of an ex Vivo Model with Clinical Application of an Epigenetic Modifier, 
Inhibiting Tumor Growth and Metastasis, in Resistant Cholangiocarcinoma" — A Case Study

The Clinical Journal of Oncology has published Dr.Nezami's Abstract (link below)
Chemoprevention and Epigenetic Multitargeted approach.
Treatment of Recurrent Cancer - Recurrence and Secondary Malignancies - 2016

M. Nezami MD,
"Epigenetic Turmor Response to Hypoxia: An Epimutation Pattern and a Method of 
Multi-Targeted Epigenetic Therapy (MTET)" - Journal of Cancer Therapy

M. Nezami MD,
"Preliminary Findings on Multi-Targeted Epigenetic Therapy (MTET) in Modifying Telomerase Activity" 
- Cancer Science; Open Access

M.Nezami MD, 
The 2nd International Conference on Oncology and Therapy (COT 2016)  
March 2 - 4, 2016 in Beijing, China. (link below)

M.Nezami MD,
poster presentation at 
Molecular Med TRI-CON 2016 (link below)
March 6 -11, 2015, San Francisco, CA.
along with the abstract: 
"Correlation of an EX VIVO model with clinical application of an epigenetic modifier, 
inhibiting tumor growth and metastasis, in resistant cholangiocarcinoma - A case study" 
Published at Journal of Cancer Therapy, 


M.Nezami MD,
14h Global cancer and anti cancer Therapy 
November 21-23, 2016 at Dubai, UAE. 

Dr.Nezami, as organizing committee member and key note speaker, presenting three abstracts:
"The epigenetic silencing of promoter genes involved with head and neck carcinomas, Translational research to reverse epigenetic pathways in oncogenesis in head and neck tumor"
"Biological interventions to interfere micro-environmental and endocrine machinery in cancer"
" Sequential targeted therapies in cancer, Applications and methods of treating actionable targets in a multi phase approach"

M.Nezami MD
"Multitargeted Epigenetic therapy (MTET) and hypoxia response elements, a turning point in radiation oncology, 2nd international conference on nuclear medicine and radiation oncology, July 27-28, 2017, Rome, Italy